Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

HEMINDERMEET SINGH

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1821345695
CMS profile
1379611
Location
PERRYSBURG, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,387.19

60 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $1,387.19 60

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

HEMINDERMEET SINGH

NPI 1821345695 · CMS profile ID 1379611

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

PERRYSBURG, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1821345695?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
HEMINDERMEET SINGH, NPI 1821345695, CMS profile ID 1379611. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1821345695?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). HEMINDERMEET SINGH, NPI 1821345695, CMS profile ID 1379611. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1821345695?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
HEMINDERMEET SINGH, NPI 1821345695, CMS profile ID 1379611, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–60 of 60 matching records. This page contains 10 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1821345695?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

60 matching records · $1,387.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 60 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–60 of 60.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $18.0003/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 768784404 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $21.5203/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763661164 CMS
Esperion Therapeutics, Inc. $15.7902/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 838407165 CMS
Amarin Pharma Inc. $16.3102/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815049523 CMS
Janssen Pharmaceuticals, Inc $19.5102/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788720981 CMS
Medtronic, Inc. $15.7202/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815570739 CMS
AstraZeneca Pharmaceuticals LP $97.4901/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829551039 CMS
Novartis Pharmaceuticals Corporation $17.3101/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813268881 CMS
Amarin Pharma Inc. $13.2201/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815155691 CMS
ABIOMED $26.0301/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848793941 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $562.76 20
PY2020 $686.37 23
PY2021 $1,387.19 60
PY2022 $3,355.16 81
PY2023 $1,561.51 49
PY2024 $930.37 16
PY2025 $341.10 6

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $80,808.09 101
PY2024 Principal investigator $111,637.19 58
PY2023 Principal investigator $94,626.44 34

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

101 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $106.69 12/31/2025 Covered Recipient Teaching Hospital
St Vincent Medical Center
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190297153
Principal investigator 1 Medtronic, Inc. $2,800.00 12/23/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
PSR-CVG No dispute reported 06/30/2026 1192311537
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748282
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 12/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748284
Principal investigator 1 Impulse Dynamics (USA) Inc. $337.50 11/13/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc-DBA Clinical Research
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy No dispute reported 06/30/2026 1214121929
Principal investigator 1 Impulse Dynamics (USA) Inc. $500.00 11/03/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc-DBA Clinical Research
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy No dispute reported 06/30/2026 1214121931
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748278
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 11/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748280
Principal investigator 1 Boehringer Ingelheim International GmbH $3,000.00 10/22/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748274
Principal investigator 1 Boehringer Ingelheim International GmbH $800.00 10/22/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748276
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748270
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 10/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748272
Principal investigator 1 Impulse Dynamics (USA) Inc. $337.50 10/01/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc-DBA Clinical Research
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy No dispute reported 06/30/2026 1214121917
Principal investigator 1 Novartis Pharmaceuticals Corporation $80.48 09/30/2025 Covered Recipient Teaching Hospital
St Vincent Medical Center
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190295412
Principal investigator 1 BIOTRONIK INC. $101.25 09/16/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365102
Principal investigator 1 BIOTRONIK INC. $227.81 09/16/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365104
Principal investigator 1 BIOTRONIK INC. $101.25 09/16/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365106
Principal investigator 1 BIOTRONIK INC. $227.81 09/16/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365108
Principal investigator 1 BIOTRONIK INC. $101.25 09/16/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365110
Principal investigator 1 BIOTRONIK INC. $227.81 09/16/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365112
Principal investigator 1 Medtronic, Inc. $3,000.00 09/12/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
PSR-CVG No dispute reported 06/30/2026 1192311535
Principal investigator 1 Medtronic, Inc. $500.00 09/04/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
PSR-CVG No dispute reported 06/30/2026 1192311533
Principal investigator 1 Impulse Dynamics (USA) Inc. $750.00 09/02/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc-DBA Clinical Research
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy No dispute reported 06/30/2026 1214121919
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748262
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 09/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748264
Principal investigator 1 BIOTRONIK INC. $101.25 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365048
Principal investigator 1 BIOTRONIK INC. $227.81 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365050
Principal investigator 1 BIOTRONIK INC. $101.25 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365052
Principal investigator 1 BIOTRONIK INC. $227.81 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365054
Principal investigator 1 BIOTRONIK INC. $101.25 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365056
Principal investigator 1 BIOTRONIK INC. $227.81 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365058
Principal investigator 1 BIOTRONIK INC. $101.25 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365060
Principal investigator 1 BIOTRONIK INC. $227.81 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365062
Principal investigator 1 BIOTRONIK INC. $101.25 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365064
Principal investigator 1 BIOTRONIK INC. $227.81 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365066
Principal investigator 1 BIOTRONIK INC. $101.25 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365068
Principal investigator 1 BIOTRONIK INC. $227.81 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365070
Principal investigator 1 BIOTRONIK INC. $101.25 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365072
Principal investigator 1 BIOTRONIK INC. $227.81 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365074
Principal investigator 1 BIOTRONIK INC. $101.25 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365076
Principal investigator 1 BIOTRONIK INC. $227.81 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365078
Principal investigator 1 BIOTRONIK INC. $101.25 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365080
Principal investigator 1 BIOTRONIK INC. $227.81 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365082
Principal investigator 1 BIOTRONIK INC. $418.50 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365084
Principal investigator 1 BIOTRONIK INC. $101.25 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365086
Principal investigator 1 BIOTRONIK INC. $227.81 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365088
Principal investigator 1 BIOTRONIK INC. $101.25 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365090
Principal investigator 1 BIOTRONIK INC. $227.81 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365092
Principal investigator 1 BIOTRONIK INC. $418.50 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365094
Principal investigator 1 BIOTRONIK INC. $455.63 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365096
Principal investigator 1 BIOTRONIK INC. $101.25 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365098
Principal investigator 1 BIOTRONIK INC. $227.81 08/08/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365100
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748258
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 08/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748260
Principal investigator 1 Impulse Dynamics (USA) Inc. $21,250.00 08/01/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc-DBA Clinical Research
Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer) No dispute reported 06/30/2026 1214121921
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748266
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 07/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748268
Principal investigator 1 Novartis Pharmaceuticals Corporation $16,793.32 06/30/2025 Covered Recipient Teaching Hospital
St Vincent Medical Center
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190294090
Principal investigator 1 Medtronic, Inc. $2,365.00 06/20/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
PSR-CVG No dispute reported 06/30/2026 1192311531
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748252
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 06/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748254
Principal investigator 1 Impulse Dynamics (USA) Inc. $200.00 05/15/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc-DBA Clinical Research
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy No dispute reported 06/30/2026 1214121923
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748248
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 05/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748250
Principal investigator 1 Boehringer Ingelheim International GmbH $1.55 04/23/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748256
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748244
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 04/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748246
Principal investigator 1 Impulse Dynamics (USA) Inc. $1,424.00 03/26/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc-DBA Clinical Research
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy No dispute reported 06/30/2026 1214121927
Principal investigator 1 Medtronic, Inc. $3,670.00 03/24/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
PSR-CVG No dispute reported 06/30/2026 1192311529
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748226
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 03/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748228
Principal investigator 1 Elutia, Inc. $2,000.00 02/18/2025 Non-covered Recipient Entity
CLINICAL RESEARCH
CPR-2218 - Cangaroo No dispute reported 06/30/2026 1254592288
Principal investigator 1 Impulse Dynamics (USA) Inc. $600.00 02/13/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc-DBA Clinical Research
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy No dispute reported 06/30/2026 1214121925
Principal investigator 1 BIOTRONIK INC. $418.50 02/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365016
Principal investigator 1 BIOTRONIK INC. $418.50 02/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365018
Principal investigator 1 BIOTRONIK INC. $418.50 02/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365020
Principal investigator 1 BIOTRONIK INC. $418.50 02/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365022
Principal investigator 1 BIOTRONIK INC. $418.50 02/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365024
Principal investigator 1 BIOTRONIK INC. $418.50 02/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365026
Principal investigator 1 BIOTRONIK INC. $418.50 02/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365028
Principal investigator 1 BIOTRONIK INC. $418.50 02/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365030
Principal investigator 1 BIOTRONIK INC. $455.63 02/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365032
Principal investigator 1 BIOTRONIK INC. $455.63 02/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365034
Principal investigator 1 BIOTRONIK INC. $455.63 02/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365036
Principal investigator 1 BIOTRONIK INC. $455.63 02/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365038
Principal investigator 1 BIOTRONIK INC. $67.50 02/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365040
Principal investigator 1 BIOTRONIK INC. $67.50 02/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365042
Principal investigator 1 BIOTRONIK INC. $67.50 02/11/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365044
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748222
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 02/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748224
Principal investigator 1 Boehringer Ingelheim International GmbH $432.00 01/31/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748230
Principal investigator 1 Boehringer Ingelheim International GmbH $432.00 01/31/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748232
Principal investigator 1 Boehringer Ingelheim International GmbH $432.00 01/31/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748234
Principal investigator 1 Boehringer Ingelheim International GmbH $432.00 01/31/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748236
Principal investigator 1 Boehringer Ingelheim International GmbH $210.00 01/31/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748238
Principal investigator 1 Novartis Pharmaceuticals Corporation $5,614.00 01/30/2025 Non-covered Recipient Entity
MERCY HEALTH
Randomized, Double-blind, Placebo-controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (VICTORION-2 PREVENT) No dispute reported 06/30/2026 1190308684
Principal investigator 1 BIOTRONIK INC. $418.50 01/14/2025 Non-covered Recipient Entity
Bon Secours Mercy Health Inc.
BIOFLOW-VII No dispute reported 06/30/2026 1244365014
Principal investigator 1 Boehringer Ingelheim International GmbH $12.00 01/14/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748242
Principal investigator 1 Boehringer Ingelheim International GmbH $12.00 01/08/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748240
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748218
Principal investigator 1 Boehringer Ingelheim International GmbH $29.00 01/01/2025 Non-covered Recipient Entity
Mercy Health St Vincent Medical Center
EASi-HF A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral BI 690517 and empagliflozin compared with placebo and empagliflozin in participants with symptomatic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) No dispute reported 06/30/2026 1220748220